Table 1.
Number of TCZ doses, disease duration at initiation of treatment, pre-TCZ and post-TCZ CRP levels, pre and post-TCZ prednisolone dose, duration of follow-up, pre and post-TCZ ITAS scores and adverse events for each case study
| Case | Number of TCZ doses | Disease duration at initiation of TCZ (months) | CRP before/after TCZ | Prednisolone dose before/after TCZ | Follow-up duration | Pretreatment ITAS score | Post-treatment ITAS score | Adverse events |
|---|---|---|---|---|---|---|---|---|
| 1 | 13 infusions of 6–8 mg/kg TCZ and 17 infusions of 4 mg/kg TCZ | 7 | 27/3 | 40 mg/3 mg | 3 years and 6 months | 19 | 0 | None |
| 2 | 12 infusions of 8 mg/kg TCZ | 3 | 13/<1 | 15 mg/3 mg | 2 years and 6 months | 6 | 0 | None |
| 3 | 16 infusions of 8 mg/kg TCZ | 0 | 200/5 | 40 mg/20 mg | 3 years and 9 months | 4 | 0 | None |
| 4 | 41 infusions of 8 mg/kg TCZ, reducing to 4 mg/kg TCZ | 1 | 28/1 | 15 mg/0 mg | 4 years and 4 months | 4 | 0 | Three episodes of transient neutropaenia |
| 5 | 5 infusions of 8 mg/kg TCZ | 20 | 13/1 | 40 mg/4 mg | 2 years and 6 months | 6 | 0 | Empyema |
| 6 | 14 infusions of 8 mg/kg TCZ | 17 | 226/7 | 15 mg/5 mg | 2 years and 6 months | 6 | 0 | None |
| 7 | 12 infusions of 8 mg/kg TCZ | 19 | 50/1 | 20 mg/0 mg | 2 years and 6 months | 6 | 0 | None |
| 8 | 5 infusions of 8 mg/kg TCZ, 2 infusions of 6 mg/kg TCZ and 4 doses of 162 mg S/C TCZ | 61 | 5.4/1 | 12 mg/2.5 mg | 1 year | 5 | 0 | None |
CRP, C reactive protein; TCZ, tocilizumab.